- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
May 18th, 2005
Bayer HealthCare, LLC, Biological Products Division (Bayer BP), and Asklepios Biopharmaceutical Inc. (AskBio), a private development-stage biotechnology company, announced today they have entered into an early-stage research and collaboration agreement to evaluate gene therapy for the treatment of hemophilia B.
AskBio is currently conducting preclinical testing of a synthetically designed biological nano particle (BNP) gene therapy, containing the factor IX gene for the treatment of hemophilia B.
|Related News Press|
Nanometrics Announces Upcoming Investor Events November 18th, 2015
Nanoparticles simplify DNA identification and quantification November 27th, 2015
Scientists 'see' detailed make-up of deadly toxin for the first time: Exciting advance provides hope for developing novel potential method of treating pneumococcal diseases such as bacterial pneumonia, meningitis and septicaemia November 25th, 2015
CEA-Leti to Share Insights into Post-7-nanometer Technologies At Workshop Prior to IEDM in Washington, D.C.: Research Includes CMOS Device Architectures, New Materials and Computing System Paradigms December 1st, 2015